当前位置: 首页 >> 检索结果
468. Diffusion Tensor CMR Assessment of the Microstructural Response to Dobutamine Stress in Health and Comparison With Patients With Recovered Dilated Cardiomyopathy.
作者: Zohya Khalique.;Andrew D Scott.;Pedro F Ferreira.;Maria Molto.;Sonia Nielles-Vallespin.;Dudley J Pennell.
来源: Circ Cardiovasc Imaging. 2026年19卷2期e018226页
Contractile reserve assessment assesses myocardial performance and prognosis. The microstructural mechanisms that facilitate increased cardiac function have not been described, but can be studied using diffusion tensor cardiovascular magnetic resonance. Resting microstructural contractile function is characterized by reorientation of aggregated cardiomyocytes (sheetlets) from wall-parallel in diastole to a more wall-perpendicular configuration in systole, with the diffusion tensor cardiovascular magnetic resonance parameter E2A defining their orientation, and sheetlet mobility defining the angle through which they rotate. We used diffusion tensor cardiovascular magnetic resonance to identify the microstructural response to dobutamine stress in healthy volunteers and then compared with patients with recovered dilated cardiomyopathy (rDCM).
469. Cell-Specific Inducible Human APOL1 Risk Variant Expression in Mice Causes Hypertension and Renal Damage.
作者: Fang Li.;Bibek Poudel.;Magaiver Andrade-Silva.;Junnan Wu.;Archana Raman.;Elisa Cruz-Morales.;Joseph Wahba.;Allison Vassalotti.;Chenyu Li.;Amin Abedini.;Konstantin A Klötzer.;Xiaoqiang Ding.;Christopher A Hunter.;Jonathan J Miner.;Katalin Susztak.
来源: Circulation. 2026年153卷6期396-414页
Black people bear a disproportionate burden of hypertension and hypertension-attributed chronic kidney disease. A role of apolipoprotein L1 (APOL1) risk variants (RVs; G1 and G2) in these conditions has been proposed, but genetic and observational studies have shown inconsistent results.
470. Molecular MRI of Collagen Enables Evaluation of Fibrosis and Therapeutic Response in Venous Thrombosis.
作者: Ling Gao.;Nadia Chaher.;Joana C Serralha.;Laura Bertolaccini.;Carlos Velasco.;Gastão Lima da Cruz.;Alexander P Morrell.;Claudia Prieto.;René M Botnar.;Alberto Smith.;Prakash Saha.;Alkystis Phinikaridou.
来源: Circ Cardiovasc Imaging. 2026年19卷1期e018784页
Fibrosis, with accumulation of type I collagen, is a hallmark of postthrombotic change after deep vein thrombosis (DVT), but tools for its direct detection are lacking. Here, we investigate whether molecular magnetic resonance imaging (MRI) using a collagen-specific gadolinium-based probe can detect and measure changes in collagen during thrombus resolution and in response to treatment in a mouse model of DVT.
471. S-Nitrosylation of Pyruvate Kinase Isoform 2 Drives Cardiac Fibrosis by Promoting Mitochondrial Fission.
作者: Shanshan Luo.;Danyu Ye.;Yan Zhang.;Yu Wang.;Miao Zhou.;Mengqi Lv.;Xiaoqian Wang.;Ke Zhong.;Yuxiao Zhang.;Lulu Hu.;Shixiu Sun.;Zhiren Zhang.;Bo Yu.;Changhao Sun.;Xiangqing Kong.;Zhengrong Huang.;Xin Chen.;Yi Han.;Liping Xie.;Yong Ji.
来源: Circulation. 2026年153卷5期338-357页
Cardiac fibrosis is a major determinant of adverse clinical outcomes of many heart diseases; currently, therapeutic strategy directly targeting fibroblasts is lacking. Nitric oxide-mediated nitrosative stress is associated with cardiac injury, and excessive nitric oxide can trigger S-nitrosylation (SNO) to specific cysteine thiol. This study aims to investigate the role of SNO in cardiac fibrosis and to identify potential therapeutic target.
472. Association Between a Novel Adult Congenital Heart Disease-Specific Patient-Reported Health Status Metric and Objective Clinical Status.
作者: Jong Mi Ko.;Shelby Kutty.;Liesbet Van Bulck.;Jamie L Jackson.;Maryanne Caruana.;Susan M Jameson.;Vaikom S Mahadevan.;Philip Moons.;Ari M Cedars.; .
来源: Circ Heart Fail. 2026年19卷1期e012860页
Although disease-specific patient-reported outcomes (PROs) are well accepted as direct and indirect clinical outcomes in various diseases, data on PRO performance in adult congenital heart disease (ACHD) are limited to nondisease-specific metrics. We, therefore, investigated the association between responses to a novel ACHD-specific PRO metric and both clinical variables and gold standard PROs.
478. Diagnostic Performance and Interpreter Experience of 1-Hour Versus 3-Hour 99mTc-HMDP Cardiac Amyloid Radionuclide Imaging: A Prospective, Blinded Comparison.
作者: Gregorio Tersalvi.;Patricia Carey.;Armin Garmany.;Christopher G Scott.;Jun Zhang.;Francisco J Maldonado.;Livia F Kruger.;Carrie B Hruska.;Geoffrey B Johnson.;Hayan Jouni.;Martin G Rodriguez-Porcel.;J Wells Askew.;John P Bois.;Kathleen A Young.;Nandan S Anavekar.;Martha Grogan.;Angela Dispenzieri.;Panithaya Chareonthaitawee.;Andrew C Homb.;Omar F AbouEzzeddine.
来源: Circ Cardiovasc Imaging. 2026年19卷1期e018745页
Guidelines recommend 3-hour cardiac amyloid radionuclide imaging (CARI) for transthyretin amyloid cardiomyopathy. Citing rapid blood clearance of 99mTc-hydroxymethylene-diphosphonate (HMDP) and efficient laboratory throughput, 1-hour imaging is increasingly practiced despite limited supporting evidence. We sought to compare diagnostic performance and interpreter experience of 1-hour versus 3-hour HMDP-CARI.
480. Use of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors in Pulmonary Hypertension.
作者: Benoit Aguado.;Grégoire Ruffenach.;Thomas Lacoste-Palasset.;Agnes Görlach.;Marianne Riou.;Mathieu Gourmelon.;Fabrice Bauer.;Marc Humbert.;Valerie Schini-Kerth.;Jean-Luc Vachiéry.;David Montani.;Fabrice Antigny.
来源: Circ Heart Fail. 2026年19卷2期e013481页
Inhibiting SGLT2 (sodium-glucose cotransporter 2) has recently transformed the medical care of patients with left heart disease. Right ventricular failure is a major predictor for patients suffering from pulmonary hypertension of various causes, including those with postcapillary pulmonary hypertension due to left heart disease. Similar to how SGLT2 inhibition benefits patients with left heart failure, recent studies have suggested utilizing these molecules to enhance right ventricular function in pulmonary hypertension. In this review, we summarize the current knowledge on the use of SGLT2is (SGLT2 inhibitors) in pulmonary hypertension. Further dedicated trials are necessary to establish their role in right ventricular pulmonary vascular disease.
|